特应性湿疹的治疗 (TREAT) 登记工作组:比较 Dupilumab 与其他全身药物治疗中度至重度湿疹安全性的方法

Angela L. Bosma(Amsterdam University Medical Centers), Carsten Flohr(King's College London), A. Manca, Jacob P. Thyssen(Bispebjerg Hospital), B.W.M. Arents(European Federation of Allergy and Airways Diseases Patients Associations), Dmitri Wall(Children's Health Ireland at Crumlin), Mette Deleuran(Aarhus University Hospital), Eulàlia Baselga(Hospital Sant Joan de Déu Barcelona), Jean‐Claude Schmit, Falko Tesch(University Hospital Carl Gustav Carus), S. Barbarot(Hotel Dieu Hospital), Louise A. A. Gerbens(Amsterdam UMC Location University of Amsterdam), T.M. Torres, I. García‐Doval(University Hospital Complex Of Vigo), Christian Vestergaard(Aarhus University), L.B. Kobyletzki, F.M. Vermeulen(Amsterdam University Medical Centers), Lawrence F. Eichenfield(University of California San Diego), Phyllis I. Spuls, Christian Apfelbacher(Heidelberg University), Alan D. Irvine(Trinity College Dublin), Åke Svensson(Skåne University Hospital), Luigi Naldi(Centro Studi GISED), Julien Sénéschal(Hôpital Saint-André), Pedro Mendes‐Bastos(Hospital do Desterro), Stephan Weidinger(University Hospital Schleswig-Holstein), Alice Roberts(Eastern Virginia Medical School), M.A. Middelkamp‐Hup(Amsterdam University Medical Centers), David Prieto‐Merino(London School of Hygiene & Tropical Medicine)
British Journal of Dermatology
June 1, 2020
Cited by 0


Related Papers